Media about us

24 April 2015

Hydrogel Corneal Inlay Promising in Pseudophakic Presbyopia

Laird Harrison / MedScape

A transparent hydrogel corneal inlay is a novel way to correct the vision of patients with pseudophakic presbyopia, a new study shows.

20 April 2015

Range of ‘uninterrupted vision’ possible with inlay

Michelle Dalton / Ophthalmology Times

Study patients with a near vision inlay implanted under a femtosecond flap achieved extended depth of focus that ranged from +1 to +3 D, said John A. Hovanesian, MD. The implant (Raindrop Near Vision Inlay, ReVision Optics) is designed to change the curvature of the overlying cornea creating a gradient of power that allows a full range of uninterrupted vision.

31 March 2015

Purple Day To Raise Epilepsy Awareness

Stephanie Stahl / CBS Philly

There is new hope for a recently discovered form of epilepsy that strikes only girls.  It’s often misdiagnosed and difficult to treat.  Thursday March 26th is designated as Purple Day to raise awareness about epilepsy.

24 March 2015

Clearside's novel eye drug delivery tech shows promise in latest clinical trial

Varun Saxena / Fierce Drug Delivery

Eyecare company Clearside Biomedical announced that patients treated with its injectable eye disease candidate demonstrated improved vision, as it tries to become the first to commercialize suprachoroidal delivery.

12 February 2015

Eyeing $14B epilepsy market, biopharma firm moves to Philly suburb

John George / Philadelphia Business Journal

The story of Marinus Pharmaceuticals, a biophamraceutical company developing new treatments for epilepsy and other neuropsychiatric disorders. The market for epilepsy treatments is estimated at more than $14 billion. Marinus is initially targeting a $4 billion subset of that market: patients with seizures who don't respond or are no longer responding to other medications in the market.

04 February 2015

Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests

Emily Wasserman / Firece Diagnostic

U.K. diagnostics outfit Atlas Genetics roped in $20 million in Series C financing to develop its ultrarapid point-of-care tests for infectious diseases, gearing up for a European launch of the product and expanding its foothold in a growing market.

03 February 2015

Omega Pharma launches Benegast line in Russia

OTC Bulletin

Omega Pharma's Benegast portfolio of OTC gastrointestinal products is now available in Russia, after the Belgian firm signed a distribution agreement with NovaMedica.

30 January 2015

Novartis and J&J back UK biotech working on 30-minute STD test

Andrew Ward / Financial Times

Novartis and Johnson & Johnson have stepped up investment in a UK molecular diagnostics company developing a 30-minute test for sexually transmitted diseases. Other groups involved in the series C financing were Consort Medical, a UK medical technology company, and three life science investment funds: RMI Partners, LSP and BB Biotech Ventures.

29 January 2015

Omega Pharma and NovaMedica to market a line of gastrointestinal products under BenegastTM brand in Russia

Yahoo Finance

Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the BenegastTM umbrella brand in Russia.

29 January 2015

Omega Pharma und NovaMedica wollen eine Reihe von Magen-Darm-Produkten unter dem Markennamen BenegastTM in Russland vermarkten

PHARMA-ZEITUNG.DE

Das russische Pharmaunternehmen NovaMedica und der in Belgien ansässige paneuropäische Pharmakonzern Omega Pharma, der sich auf Entwicklung und Vertrieb rezeptfrei erhältlicher Gesundheits- und Körperpflegeprodukte konzentriert, haben eine Partnerschaftsvereinbarung unterzeichnet, gemäß der NovaMedica exklusive Rechte auf Bewerbung, Vertrieb und Verkauf einer Reihe rezeptfreier Magen-Darm-Produkte unter dem Dachmarkennamen BenegastTM in Russland erhält.